Clinical Study onShugan Liqi Qingqiu Decoction in the Treatment of Allergic Rhinitis
10.3969/j.issn.1005-5304.2016.07.010
- VernacularTitle:疏肝理气清鼽汤治疗变应性鼻炎临床研究
- Author:
Yujuan JIAO
;
Lianyong ZHANG
;
Xueliang CUI
- Publication Type:Journal Article
- Keywords:
allergic rhinitis;
ShuganLiqiQingqiu Decoction;
RCT
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2016;23(7):38-41
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety ofShugan Liqi Qingqiu Decoction in the treatment of allergic rhinitis.Methods Totally 74 patients were randomly divided into treatment group and control group in a 1:1 ratio. The treatment group received the prescription ofShuganLiqiQingqiu Decoction, and control group was given loratadine tablets orally, 7 days as a course of treatment and 3 courses successive. After treatment, the visual analogue scale (VAS), Rhinocoujunctivitis Quality of Life Questionaire (RQLQ), Specific IgE (SIgE) values and total effective rate were measured to evaluate the clinical efficacy, and the total number of cases of adverse reactions was statistically analyzed.Results After all the patients were researched, the total effective rate of treatment group was 86.49% (32/37) in the treatment group and 89.19% (33/37) in control group, without statistical difference (P>0.05). There was statistical difference in VAS and RQLQ between before and after treatment in the two groups (P<0.05). After treatment, there was no statistical difference (P>0.05) in VAS and was statistical difference in RQLQ (P<0.05) in the two groups. There was no statistical difference (P>0.05) in SIgE in the treatment group, and was statistical difference (P<0.05) in control group. There was no significant difference (P>0.05) in SIgE between the two groups after treatment. There was no adverse reaction except for 2 patients in the treatment group with mild diarrhea. Conclusion ShuganLiqiQingqiu Decoction has good clinical efficacy and safety for the treatment of allergic rhinitis.
